Tildipirosin Property

Melting point:

>110°C (dec.)

Boiling point:

846.8±65.0 °C(Predicted)

Density 

1.15

storage temp. 

2-8°C

solubility 

Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly)

form 

Solid

pka

13.18±0.70(Predicted)

color 

Off-White to Pale Beige

InChI

InChI=1/C41H71N3O8/c1-8-35-32(26-44-20-13-10-14-21-44)23-27(2)15-16-33(45)28(3)24-31(17-22-43-18-11-9-12-19-43)40(29(4)34(46)25-36(47)51-35)52-41-39(49)37(42(6)7)38(48)30(5)50-41/h15-16,23,28-32,34-35,37-41,46,48-49H,8-14,17-22,24-26H2,1-7H3/b16-15+,27-23+/t28-,29+,30-,31+,32-,34-,35-,37+,38-,39-,40-,41+/s3

InChIKey

HNDXPZPJZGTJLJ-IGVBWUSTNA-N

SMILES

[C@@H]1(O[C@H]2[C@@H](CCN3CCCCC3)C[C@@H](C)C(=O)C=CC(C)=C[C@H](CN3CCCCC3)[C@@H](CC)OC(=O)C[C@@H](O)[C@@H]2C)O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O |t:18,21,&1:0,2,3,13,22,30,37,39,42,44,46,50,r|

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

H315Causes skin irritation

H319Causes serious eye irritation

H360May damage fertility or the unborn child

H372Causes damage to organs through prolonged or repeated exposure

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P308+P313IF exposed or concerned: Get medical advice/attention.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

Tildipirosin Chemical Properties,Usage,Production

Description

Tildiprosin is an antibiotic derived from a tylosin derivative by iodination and reaction with piperidine. Tildiprosin provides good protection against Bartonella henselae in livestock. Treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin. The introduction of a third basic moiety into the tylosin core provides a wider spectrum of antibiotic action than the dibasic analogues such as tilmicosin. Tildipirosin′s interaction with the ribosomal site of action differs from that of tylosin and tilmicosin.

Uses

Tildiprosin is a semi-synthetic antibiotic derived from a tylosin derivative by iodination and reaction with piperidine. The introduction of a third basic moiety into the tylosin core provides a wider spectrum of antibiotic action than the dibasic analogues such as tilmicosin, in particular good protection against Pasteurella in livestock. Tildipirosin’s interaction with the ribosomal site of action differs from that of tylosin and tilmicosin.

Uses

Tildipirosin is a novel 16-membered-ring macrolide used in veterinary medicine. Tildipirosin treats bacterial pathogens including Mannheimia haemolytica and Pasteurella multocida that cause respiratory tract infections in cattle and swine (BRD Bovine Respiratory Disease).

Biochem/physiol Actions

Tildipirosin has additionally proven effective against Histophilus somni, Bordetella bronchiseptica, Actinobacillus pleuropneumoniae, and Haemophilus parasuis, which can also be associated with animal respiratory diseases.

Mechanism of action

The mechanism of action of Tildipirosin consists of the inhibition of the bacterial protein synthesis as a consequence of binding to 23S ribosomal RNA for 50S subunit.

Side effects

In target animal safety studies, administration of the maximum recommended injection volume (5 ml) occasionally caused slight swellings at the injection site that were not painful on palpation. Swellings persisted for up to 3 days. Pathomorphological injection site reactions resolved completely within 21 days. During clinical trials, pain on injection and injection site swellings were seen very commonly in treated pigs. These swellings resolved within 1 to 6 days. During clinical trials, treatment caused shock symptoms in 2 out of 1048 animals. These symptoms quickly resolved in one animal, but led to death in the other animal.